Drugs / AZD0292
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07222254 | Dec 2025 → Jul 2026 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06311760 | Apr 2024 → Feb 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07088926 | Nov 2025 → Dec 2027 expected | bronchiectasis | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0292 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07088926 ↗ |
| Modality | Monoclonal antibody | “AZD0292 is a bispecific IgG1k mAb” NCT07088926 ↗ |
| Route | Intravenous | “via IV infusion” NCT06311760 ↗ |